Trial Profile
A Phase 1, Open-Label, Crossover Study to Evaluate the Pharmacokinetics and Safety of GSK1265744 and Rilpivirine and Dolutegravir and Rilpivirine in Healthy Adult Subjects.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 18 Jul 2023
Price :
$35
*
At a glance
- Drugs Cabotegravir (Primary) ; Dolutegravir (Primary) ; Rilpivirine (Primary)
- Indications HIV infections
- Focus Pharmacokinetics
- Sponsors ViiV Healthcare
- 26 Aug 2013 Results published in the Antimicrobial Agents and Chemotherapy.
- 01 Jun 2012 Actual number of patients changed from 44 to 56, as reported by ClinicalTrials.gov.
- 22 Mar 2012 Actual patient number (44) added as reported by ClinicalTrials.gov.